Man Group plc Invests $3.17 Million in Omnicell, Inc. $OMCL

Man Group plc purchased a new position in Omnicell, Inc. (NASDAQ:OMCL) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 76,339 shares of the company’s stock, valued at approximately $3,170,000. Man Group plc owned 0.17% of Omnicell at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Versant Capital Management Inc grew its holdings in Omnicell by 38.7% during the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock valued at $44,000 after purchasing an additional 294 shares during the period. Cerity Partners LLC raised its stake in shares of Omnicell by 4.9% in the fourth quarter. Cerity Partners LLC now owns 7,613 shares of the company’s stock valued at $345,000 after buying an additional 354 shares during the period. Thrivent Financial for Lutherans lifted its position in shares of Omnicell by 1.2% during the 2nd quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company’s stock valued at $1,013,000 after buying an additional 424 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Omnicell by 0.3% during the 3rd quarter. Legal & General Group Plc now owns 158,399 shares of the company’s stock worth $4,823,000 after acquiring an additional 448 shares during the period. Finally, California State Teachers Retirement System grew its stake in shares of Omnicell by 1.7% during the 2nd quarter. California State Teachers Retirement System now owns 42,552 shares of the company’s stock worth $1,251,000 after acquiring an additional 692 shares during the period. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell Stock Performance

NASDAQ:OMCL opened at $35.16 on Tuesday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.43 and a current ratio of 1.64. Omnicell, Inc. has a 52-week low of $29.06 and a 52-week high of $55.00. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of 41.86, a PEG ratio of 0.83 and a beta of 0.98. The business’s fifty day moving average is $39.73 and its 200 day moving average is $39.32.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, July 30th. The company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.47 by $0.47. The business had revenue of $312.21 million during the quarter, compared to the consensus estimate of $310.21 million. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The firm’s revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.45 EPS. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Research analysts predict that Omnicell, Inc. will post 1.41 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on OMCL. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. Piper Sandler reiterated an “overweight” rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. Wells Fargo & Company lowered their price target on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Finally, Zacks Research cut shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $57.86.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.